Can administrative data be used to measure chemotherapy side effects?

References

• Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Handbooks in Health Economic Evaluation. 2010. Oxford: Oxford University Press
   Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005;365(9453):82-93
   PubMed Web of Science ®Google Scholar
• Drummond MF. Experimental versus observational data in the economic evaluation of pharmaceuticals. Med Decis Making 1998;18(Suppl 2):S12-18
   Google Scholar
• Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997;315(7115):1059
   PubMedGoogle Scholar
• Garrison LPJr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007;10(5):326-35
   PubMed Web of Science ®Google Scholar
• MacDonald D, et al. Using administrative databases in oncological population health research: a Canadian experience. OA Cancer 2013;1(1):3
   Google Scholar
• OECD. OECD Health Data 2005. 2005. OECD Publishing; Paris
   Google Scholar
• Chabner BA, Roberts TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5(1):65-72
   PubMed Web of Science ®Google Scholar
• OECD. Pharmaceutical expenditure, in Health at a Glance 2011: OECD Indicators. 2011. OECD Publishing; Paris
   Google Scholar
• Ioannidis JPA, Lau J. Completeness of Safety Reporting in Randomized Trials: an Evaluation of 7 Medical Areas. JAMA 2001;285(4):437-43
   PubMed Web of Science ®Google Scholar
• Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006;24(24):3933-8
   PubMedGoogle Scholar
• Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169(19):1756-61
   PubMed Web of Science ®Google Scholar
• Lopez-Jimenez J, Martín-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91(1):84-91
   PubMedGoogle Scholar
• Pearce A, Haas M, Viney R. Are the true impacts of adverse events considered in economic models of antineoplastic drugs? a systematic review. Appl Health Econ Health Policy 2013:1-19
   Google Scholar
• Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clinical Oncol 2002;20(24):4636-42
   PubMedGoogle Scholar
• Gwede CK, Johnson DJ, Daniels SS, Trotti A. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag 2002;11(2):15-21
   PubMedGoogle Scholar
• Private Health Insurance Administration Council. Quarterly Statistics March 2013. 2013. Canberra
   Google Scholar
• Centre for Health Record Linkage. Centre for Health Record Linkage. 2011. Available from: www.cherel.org.au/
   Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03. 2010, National Institute of Health.
   Google Scholar
• Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire based study. Lancet Oncol 2006;7(11):903-9
   PubMed Web of Science ®Google Scholar
• Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19(2):203-8
   PubMedGoogle Scholar
• Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95(1):155-63
   PubMed Web of Science ®Google Scholar
• Beusterien K, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8(1):50
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Benson AB, Catalano R, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 2000;19(2):118-29
   PubMed Web of Science ®Google Scholar
• Benson AB3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clinical Oncol 2004;22(14):2918-26
   PubMedGoogle Scholar
• Maroun J, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 2007;14(1):13-20
   PubMedGoogle Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28(33):4996-5010
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Cancer- and Chemotherapy- Induced Anemia. National Comprehensive Cancer Network; Fort Washington: 2010
   Google Scholar
• Turner R, Anglin P, Burkes R, et al. Epoetin Alfa in Cancer Patients: evidence-Based Guidelines. J Pain Symptom Manage 2001;22(5):954-65
   PubMedGoogle Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43(2):258-70
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clinical Oncol 2006;24(18):2932-47
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Roila F, Tonato M, et al. Multinational Association of Supportive Care in Cancer and European Society of Medical Oncology Antiemetic Guideline. 2010;Support Care Cancer 2005;13(2):77-9
   Google Scholar
• National Comprehensive Cancer Network. Antiemesis. National Comprehensive Cancer Network; Fort Washington: 2010
   Google Scholar
• Henry DH, Viswanathan HN, Elkin EP, et al. Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the US. Support Care Cancer 2008;16(7):791-801
   PubMed Web of Science ®Google Scholar
• Guerriere DN, Ungar WJ, Corey M, et al. Evaluation of the ambulatory and home care record: Agreement between self-reports and administrative data. Int J Technol Assess Health Care 2006;22(02):203-10
   PubMedGoogle Scholar
• Quan H, Parsons GA, Ghali WA, Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002;40(8):675-85
   PubMed Web of Science ®Google Scholar
• van Dalen MT, Suijker JJ, MacNeil-Vroomen J, et al. Self-report of healthcare utilization among community-dwelling older persons: a prospective cohort study. PLoS ONE 2014;9(4):e93372
   Google Scholar
• Bent S, Padula A, Avins AL. Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006;144(4):257-61
   PubMed Web of Science ®Google Scholar
• Berger ML, Martin BC, Husereau D, et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NCP good practice task force report. Value in health 2014;17:143-56
   PubMed Web of Science ®Google Scholar
• Rovithis D. Do health economic evaluations using observational data provide reliable assessment of treatment effects? Health Econ Rev 2013;3(1):21
   PubMedGoogle Scholar
• Earle CC, Park ER, Lai B, et al. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clinical Oncol 2003;21(6):1133-8
   PubMed Web of Science ®Google Scholar
• Wasiak R, Pransky G, Verma S, Webster B. Recurrence of low back pain: definition-sensitivity analysis using administrative data. Spine 2003;28(19):2283-91
   PubMedGoogle Scholar